Show simple item record

dc.contributor.authorGonzález-Giraldo Y.
dc.contributor.authorForero D.A.
dc.contributor.authorEcheverria V.
dc.contributor.authorGonzalez J.
dc.contributor.authorÁvila-Rodriguez M.
dc.contributor.authorGarcia-Segura L.M.
dc.contributor.authorBarreto G.E.
dc.date.accessioned2020-09-02T22:19:23Z
dc.date.available2020-09-02T22:19:23Z
dc.date.issued2016
dc.identifier10.1016/j.arr.2016.04.004
dc.identifier.citation28, , 37-45
dc.identifier.issn15681637
dc.identifier.urihttps://hdl.handle.net/20.500.12728/4722
dc.descriptionSenescence plays an important role in neurodegenerative diseases and involves key molecular changes induced by several mechanisms such as oxidative stress, telomere shortening and DNA damage. Potential therapeutic strategies directed to counteract these molecular changes are of great interest for the prevention of the neurodegenerative process. Telomerase is a ribonucleoprotein composed of a catalytic subunit (TERT) and a RNA subunit (TERC). It is known that the telomerase is involved in the maintenance of telomere length and is a highly expressed protein in embryonic stages and decreases in adult cells. In the last decade, a growing number of studies have shown that TERT has neuroprotective effects in cellular and animal models after a brain injury. Significantly, differences in TERT expression between controls and patients with major depressive disorder have been observed. More recently, TERT has been associated with the decrease in reactive oxygen species and DNA protection in mitochondria of neurons. In this review, we highlight the role of TERT in some neurodegenerative disorders and discuss some studies focusing on this protein as a potential target for neuroprotective therapies. © 2016 Elsevier B.V.
dc.language.isoen
dc.publisherElsevier Ireland Ltd
dc.subjectNeuroprotection
dc.subjectOxidative stress
dc.subjectSenescence
dc.subjectTelomerase
dc.subjectTelomeres
dc.subjectags 499
dc.subjectcotinine
dc.subjectestradiol
dc.subjectmontelukast
dc.subjectneuroprotective agent
dc.subjectnicotine
dc.subjectraloxifene
dc.subjecttamoxifen
dc.subjecttelomerase
dc.subjecttibolone
dc.subjectunclassified drug
dc.subjectneuroprotective agent
dc.subjectreactive oxygen metabolite
dc.subjecttelomerase
dc.subjectastrocyte
dc.subjectbrain nerve cell
dc.subjectcell aging
dc.subjectcellular distribution
dc.subjectcentral nervous system
dc.subjectdegenerative disease
dc.subjectenzyme active site
dc.subjectenzyme activity
dc.subjectgenetic variability
dc.subjecthuman
dc.subjecthypoxic ischemic encephalopathy
dc.subjectmicroglia
dc.subjectmitochondrial targeting signal
dc.subjectneuroprotection
dc.subjectnonhuman
dc.subjectoxidative stress
dc.subjectpleiotropy
dc.subjectprotein expression
dc.subjectprotein localization
dc.subjectprotein phosphorylation
dc.subjectprotein targeting
dc.subjectReview
dc.subjectsenescence
dc.subjecttelomere
dc.subjecttelomere homeostasis
dc.subjecttelomere shortening
dc.subjectaging
dc.subjectanimal
dc.subjectcentral nervous system
dc.subjectDNA damage
dc.subjectdrug effects
dc.subjectgenetics
dc.subjectmetabolism
dc.subjectNeurodegenerative Diseases
dc.subjectphysiology
dc.subjectAging
dc.subjectAnimals
dc.subjectCentral Nervous System
dc.subjectDNA Damage
dc.subjectHumans
dc.subjectNeurodegenerative Diseases
dc.subjectNeuroprotective Agents
dc.subjectOxidative Stress
dc.subjectReactive Oxygen Species
dc.subjectTelomerase
dc.subjectTelomere
dc.subjectTelomere Shortening
dc.titleNeuroprotective effects of the catalytic subunit of telomerase: A potential therapeutic target in the central nervous system
dc.typeReview


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record